Jump to content

Rongliflozin

Add links
From Wikipedia, the free encyclopedia

Rongliflozin
Legal status
Legal status
  • Investigational
Identifiers
  • (1R,2S,3S,4R,5S)-5-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-1-[(1R)-1-hydroxyethyl]-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol
CAS Number
PubChem CID
UNII
ChEMBL
Chemical and physical data
FormulaC23H27ClO7
Molar mass450.91 g·mol−1
3D model (JSmol)
  • CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)[C@@]34[C@@H]([C@H]([C@@H]([C@@](O3)(CO4)[C@@H](C)O)O)O)O)Cl
  • InChI=1S/C23H27ClO7/c1-3-29-17-7-4-14(5-8-17)10-15-11-16(6-9-18(15)24)23-21(28)19(26)20(27)22(31-23,12-30-23)13(2)25/h4-9,11,13,19-21,25-28H,3,10,12H2,1-2H3/t13-,19+,20+,21-,22-,23+/m1/s1
  • Key:KODGTDKHPNYCCJ-YWRILDCISA-N

Rongliflozin is an SGLT2 inhibitor developed as a potential treatment for diabetes.[1][2]

References

[edit]
  1. ^ Zhang H, Liu J, Zhu X, Li X, Chen H, Wu M, et al. (May 2020). "A Phase I Study on the Pharmacokinetics and Pharmacodynamics of DJT1116PG, a Novel Selective Inhibitor of Sodium-glucose Cotransporter Type 2, in Healthy Individuals at Steady State". Clinical Therapeutics. 42 (5): 892–905.e3. doi:10.1016/j.clinthera.2020.03.007. PMID 32265061.
  2. ^ Zhang H, Zhu X, Li X, Chen H, Wu M, Li C, et al. (February 2020). "Pharmacokinetics and pharmacodynamics of rongliflozin, a novel selective inhibitor of sodium-glucose co-transporter-2, in people with type 2 diabetes mellitus". Diabetes, Obesity & Metabolism. 22 (2): 191–202. doi:10.1111/dom.13887. PMID 31588657.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Rongliflozin&oldid=1233320034"